Skip to main navigation

Main Nav

About Us
Scientific Platform
Our Pipeline
Career Opportunities
Investors & Media

Press Releases

IR Nav

Overview
Press Releases
Events
Presentations
Annual Reports
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
FAQs
Email Alerts
Investor Contact

Shareholder Tools

Press Releases

Year

Gritstone Oncology Receives Notice of Allowance from U.S. Patent and Trademark Office on its Core Patent Application for Tumor Antigen Prediction Model

May 7, 2018

Gritstone Oncology to Present First Data Bridging Tumor Antigen Identification and Potent Immunotherapy Delivery in Primates at 2018 AACR Annual Meeting

April 12, 2018

Gritstone Oncology Appoints Jayant Aphale, Ph.D. as Executive Vice President of Technical Operations

March 19, 2018

Gritstone Oncology Appoints Jean-Marc Bellemin as Chief Financial Officer

January 23, 2018

Gritstone Oncology Opens New State-of-the-Art Personalized Cancer Immunotherapy Manufacturing Facility

November 28, 2017

Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients

October 18, 2017

FierceBiotech Names Gritstone Oncology as a “Fierce 15” Biotechnology Company of 2017

September 26, 2017

Gritstone Oncology Secures $92.7 Million In Series B Financing

September 7, 2017

Gritstone Oncology Expands Scientific Advisory Board with Appointment of Immuno-Oncology Experts James L. Gulley and Alessandro Sette

June 1, 2017

Gritstone Oncology Appoints Raphaël F. Rousseau, M.D., Ph.D., as Chief Medical Officer

May 3, 2017

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Page 5
Current page 6
Page 7
Next page
Last page

© 2020 Gritstone Oncology |

Footer Links

Privacy Policy
Terms of Use
Contact

socials

Top